Abstract

During the past year, the VRC's Vector Core created and tested new vaccine vectors expressing different HIV protein, including structural and envelope proteins. In addition,different methods and routes of administration as well as prime/boost combinations were tested to further optimize HIV vaccine strategies. New adenoviral,LCMV and BCG vectors were tested, as well as administration via intradermal and mucosal delivery. Several candidate vaccines elicited promising immunogenicity data in preliminary studies and are being tested further. Antibodies that inhibit or prevent infection were developed,and initial testing performed. Specific accomplishments include: Assessment of recombinant lymphocytic choriomeningitis virus (rLCMV)as a vaccine to prevent HIV infections. Different prime boost vectors encoding HIV-1 Env including DNA, recombinant adenovirus serotype 5 (rAd5) or alternative serotype rAd for priming followed by boosting with a replication-defective vector were compared. T cell immunogenicity was assessed by intracellular cytokine staining or by analyzing tetramer positive cells.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI005002-08
Application #
7964795
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2009
Total Cost
$2,695,631
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Zhou, Tongqing; Doria-Rose, Nicole A; Cheng, Cheng et al. (2017) Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Rep 19:719-732
Chuang, Gwo-Yu; Geng, Hui; Pancera, Marie et al. (2017) Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. J Virol 91:
Cheng, Cheng; Pancera, Marie; Bossert, Adam et al. (2016) Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. J Virol 90:2740-55
Saunders, Kevin O; Pegu, Amarendra; Georgiev, Ivelin S et al. (2015) Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol 89:5895-903
Georgiev, Ivelin S; Joyce, M Gordon; Yang, Yongping et al. (2015) Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. J Virol 89:5318-29
Lynch, Rebecca M; Wong, Patrick; Tran, Lillian et al. (2015) HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol 89:4201-13
Cheng, Cheng; Wang, Lingshu; Ko, Sung-Youl et al. (2015) Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. Vaccine 33:7344-51
Ko, Sung-Youl; Pegu, Amarendra; Rudicell, Rebecca S et al. (2014) Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514:642-5
Pancera, Marie; Zhou, Tongqing; Druz, Aliaksandr et al. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:455-61
Pegu, Amarendra; Yang, Zhi-yong; Boyington, Jeffrey C et al. (2014) Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 6:243ra88

Showing the most recent 10 out of 18 publications